Search / Trial NCT06614582

Long-term Evaluation of Nasopharyngeal Airway in Hypotonia

Launched by UNIVERSITY OF MICHIGAN · Sep 23, 2024

Trial Information

Current as of October 09, 2024

Not yet recruiting

Keywords

Self Supporting Nasopharyngeal Airway (Ss Npa) Sleep Study Difficulty Breathing Obstructive Sleep Apnea Cerebral Palsy Down Syndrome Trisomy 21

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Children with Hypotonic Upper Airway Obstruction (HUAO) that took part in the original study (HUM00189669/NCT04846400 or HUM00220966/NCT05527652 trials)
  • * Willingness to continue device usage.
  • * Confirmed diagnosis of OSA (apnea/hypopnea index; AHI \> 10 or AHI \>5 with lowest oxygen level ≤75%)
  • * At least one symptom of OSA (such as frequent snoring, daytime sleepiness, or hyperactive/inattentive behaviors)
  • * Previous adenotonsillectomy (unless tonsillectomy not possible)
  • * Tonsil size 2+ or smaller
  • Exclusion Criteria:
  • * Participants that were non-compliant with the Self-Supporting Nasopharyngeal Airway (ssNPA) device during participation in the parent study listed above
  • * Any medical reason why ssNPA therapy may not be suitable
  • * Active COVID 19 infections Moderate/severe tracheobronchomalacia
  • * Need for anticoagulative therapy
  • * Bleeding disorder
  • * Restrictive thoracic disorders

About University Of Michigan

The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.

Locations

Ann Arbor, Michigan, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0